We previously carried out a phase I/II clinical trial and an open-label, randomized, phase II trial to determine the safety, immunogenicity and preliminary clinical efficacy of peptide-based vaccination in combination with low-dose non continuous interferon (IFN)-α2b, with or without dacarbazine preconditioning (1 day before vaccination), in patients with resected stage III, IVM1a and IVM1b melanoma (14, 15). Here, IFNA2 is linked to melanoma.